Advances and Challenges in Understanding MicroRNA Function in Tauopathies: A Case Study of miR-132/212

Emmanuelle Boscher1,2†, Julia Hernandez-Rapp1,2†, Serena Petry1,2, Remi Keraudren1,2, Sara Rainone1,2, Andréanne Loiselle1,2, Claudia Goupil1,2, Andréanne Turgeon1,2, Isabelle St-Amour1,2, Emmanuel Planèl1,2 and Sébastien S. Hébert1,2*

1Axe Neurosciences, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC, Canada, 2Département de Psychiatrie et Neurosciences, Université Laval, Québec, QC, Canada

In the past decade, several groups have reported that microRNAs (miRNAs) can participate in the regulation of tau protein at different levels, including its expression, alternative splicing, phosphorylation, and aggregation. These observations are significant, since the abnormal regulation and deposition of tau is associated with nearly 30 neurodegenerative disorders. Interestingly, miRNA profiles go awry in tauopathies such as Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal dementia. Understanding the role and impact of miRNAs on tau biology could therefore provide important insights into disease risk, diagnostics, and perhaps therapeutics. In this Perspective article, we discuss recent advances in miRNA research related to tau. While proof-of-principle studies hold promise, physiological validation remains limited. To help fill this gap, we describe herein a pure tauopathy mouse model deficient for the miR-132/212 cluster. This miRNA family is strongly downregulated in human tauopathies and shown to regulate tau in vitro and in vivo. No significant differences in survival, motor deficits or body weight were observed in PS19 mice lacking miR-132/212. Age-specific effects were seen on tau expression and phosphorylation but not aggregation. Moreover, various miR-132/212 targets previously implicated in tau modulation were unaffected (GSK-3β, Foxo3a, Mapk1, p300) or, unexpectedly, reduced (Mapk3, Foxo1, p300, Calpain 2) in miR-132/212-deficient PS19 mice. These observations highlight the challenges of miRNA research in living models, and current limitations of transgenic tau mouse models lacking functional miRNA binding sites. Based on these findings, we finally recommend different strategies to better understand the role of miRNAs in tau physiology and pathology.

Keywords: tau, microRNA, PS19, miR-132, tauopathies

INTRODUCTION

Tauopathies comprise a group of ∼30 neurodegenerative disorders characterized by the pathological accumulation of hyperphosphorylated and insoluble tau in neurons and/or glia (1). In humans, the MAPT gene encoding tau contains 16 exons, with the first exon as part of the promoter region and last exons comprising the 3′ untranslated region (3′UTR). The tau mRNA
transcript undergoes different steps of regulation including fine-tuning of expression, alternative splicing of exons 2, 3, and 10, and multiple levels of phosphorylation (1). These modifications play a central role in tau function related to the binding and stabilization of microtubules (2). While rare mutations in the MAPT gene underlie familial forms of disease (e.g., frontotemporal dementia with parkinsonism-17), the majority of tauopathies are sporadic and of unknown origin. The most prevalent tauopathy is Alzheimer’s disease (AD), where tau aggregates into neurofibrillary tangles (NFTs) in conjunction with amyloid-β (Aβ) plaques (3). So far, it remains uncertain which mechanisms surrounding tau biology contribute to brain degeneration and clinical outcomes.

The small (~21 nts) non-coding microRNAs (miRNAs) play a fundamental role in brain development, function, and survival (4, 5). They function as part of the endogenous RNA-induced silencing complex (RISC) to control protein output. This occurs by binding to mRNA transcripts within the 3′UTR to promote translational repression or mRNA degradation. Interestingly, the brain contains a rich repertoire of miRNAs, some of which go awry in tauopathies. While affected miRNAs have been associated with tau pathology in humans and animal models, the cause-consequence relationship between these factors remains ill defined. Nonetheless, specific miRNAs have emerged as promising diagnostic and therapeutic targets in tauopathies (6–8).

Several methods currently exist to study miRNA:mRNA interaction and biological function (9). These range from bioinformatic predictions, 3′UTR reporter assays, overexpression and inhibition studies, to cross-linking with immunoprecipitation (CLIP). The most common and straightforward approach is introducing a mutation within the miRNA target site (in particular the seed sequence) to inhibit miRNA:mRNA binding and gene expression regulation. This strategy is however quite challenging in vivo with only one known report in the mammalian brain (10), unrelated to tau. Most miRNA literature is therefore based on indirect or artificial paradigms that await physiological validation.

In this Perspective article, we provide an overview of advances related to the regulation of tau by miRNAs. As the reader will notice, the literature is promising but lacks consistency and in vivo validation. To aid in this effort, we also describe herein PS19 mice deficient for the miR-132-212 cluster. This is the first description of a pure tauopathy mouse model genetically deficient for specific miRNAs. Some paradoxical results obtained in this model prompted us to address certain “barriers” regarding experimental reproducibility and propose guidelines to help move forward this line of research.

**PERSPECTIVE ARTICLE**

**Evidence That tau Is a MicroRNA Target**

The human MAPT gene produces two 3′UTR isoforms of 256 and 4,163 nucleotides in length (11). The longest isoform is conserved and highly expressed in the brain (frontal cortex) (12). Previous studies have shown that different domains within the tau 3′UTR are important for mRNA structure, stability, and transport (13–15). Since tau is a dose-sensitive gene candidate (16, 17), and that its mis-regulation is associated with disease (18), it seems logical that different regulatory mechanisms have evolved to keep tau expression levels in check.

A simple search of common miRNA target site prediction programs (e.g., targetscan.org) reveals several conserved binding sites within the tau 3′UTR. Consistent with this, a handful of miRNAs have been shown to bind to tau mRNA, including miR-132 (19, 20), miR-34 (11), miR-186 (21), miR-219 (22), miR-362 (23), and miR-766 (23). Most groups have relied on 3′UTR luciferase reporter assays and mutagenesis to confirm gene expression regulation *in vitro*. One report could not confirm the interaction between miR-132 and its corresponding seed region however (11). Whether this is due to technical issues (type of mutagenesis, miRNA titration) or unknown regulatory mechanisms remains to be determined. Taken together, these observations provide strong evidence that tau is a *bone fide* miRNA target that now awaits *in vivo* validation using gene editing technologies. Interestingly, the ratio between tau 3′UTR isoforms seems to differ between healthy and AD brain (12, 24). Whether this results in altered miRNA regulation requires further investigation.

**MicroRNA Regulation of tau Pre- and Post-translational Modifications: Unlimited Possibilities?**

As stated above, alternative splicing and phosphorylation are key elements of tau regulation and function. Nearly 15 miRNAs have been implicated so far in the *indirect* modulation of tau (8, 25). These “tau modifier” genes are mostly kinases, and include Gsk-3β [miR-132 (26), miR-125b (27), miR-124 (28), miR-219 (29, 30), miR-138 (31)], Cdk5 [miR-125b (32, 33), miR-26b (34), miR-195 (35)], Erk [miR-125b (32)], Itpk [miR-132 (36)], Fyn [miR-369 (37), miR-106b (38)], and Rock1 [miR-146a (39)]. Tau phosphatases include: Ppp1ca [miR-125b (32)] and Ptpn1 [miR-124 (40)]. Other genes *a priori* unrelated to kinases or phosphatases include p300 [miR-132 (26)], RbbFox1 [miR-132 (26), Nos1 [miR-132 (41)], Bnfd [miR-322 (42)], Raro [miR-138 (31)], Cacna1c [miR-137 (43)], Uchl1 [miR-922 (44)], and HspB8 [miR-425 (45)].

The number of miRNA targets involved in tau splicing (exon 10) is more limited. These include Ptbp1 [miR-132 (19)] and yet unidentified genes [miR-124, miR-9, miR-153, miR-137 (19)]. Overall, while some miRNAs (miR-132, miR-125b, miR-124) and target genes (Gsk-3β, Cdk5) seem recurrent, no clear pathway or trigger stands out and *in vivo* validation is again largely lacking. To study miRNAs in living organisms, especially in mammals, is particularly challenging since most tau modifier genes contain several miRNA-binding sites themselves (e.g., Gsk-3β 3′UTR contains ~100 putative miRNA sites). Thus, the amount of potential miRNA:mRNA networks surrounding tau biology seem almost limitless, at least in appearance.

Indeed, bioinformatics and *in vitro* paradigms need to be tested and experimentally validated using *in vivo* models.
recapitulating the cellular and miRNA-target interaction networks occurring in human physiology and pathology. Furthermore, not all miRNAs modulated in cultured cells are biologically relevant since expressed at low or insufficient levels in vivo (as with their target counterparts). Also, not all target genes are sensitive to small changes in mRNA transcript or protein levels (46–48). This said, it is likely that only a limited number of miRNAs and dosage-sensitive genes are involved in the physiological regulation of tau (see also Barrier 2 below). This adds to other potential modes of miRNA action implicating competitive endogenous RNAs (ceRNA) (49) as well as cooperative binding and target site competition (50). An important step will be to identify the functional miRNA:mRNA pairs within the biological networks in brain cells.

A Mouse Model to Study miRNA Deficiency in Pure Tauopathies

Recent RNA deep-sequencing efforts have shown that ~50–100 miRNAs are expressed at moderate to high levels in the mouse and human brain (51–53). Several of these are enriched in neurons, glia, or other cell types (54). Given the diversity of tau pathologies, selecting a candidate miRNA, and biological model for functional studies is a daunting task. Interestingly, accumulating studies highlight the potential biological importance of specific miRNAs. For example, loss of the miR-132/212 cluster shows a strong correlation with memory decline, NFTs, and Braak (tau pathological) stages in AD (20, 26, 51, 55–59). This cluster is also downregulated in other tauopathies such as frontotemporal dementia (60) and progressive supranuclear palsy (19). Deletion of the miR-132/212 cluster, or inhibition of neuron-specific miR-132, causes an increase in tau phosphorylation or aggregation in 3xTg-AD and APP/PS1 mice (36, 41, 61). Inversely, the brain delivery of miR-132 using viruses reduced tau pathologies in 3xTg-AD (61) and PS19 (26) mice. While promising, different target genes and underlying mechanisms have been proposed, and therefore the mode of action remains unresolved.

To further build on these findings, we investigated the effects of genetically removing the miR-132/212 cluster in PS19 mouse, a model of pure tauopathy that overexpresses human tau with a mutation (P301S) that causes FTD in humans (62). This model develops motor deficits, tau deposition, and neuronal loss between 6 and 12 months, with a high mortality rate at late-stage disease.

We observed no significant differences in mouse survival (Figure 1A) and motor deficits (Figure 1B) following miR-132/212 deletion in PS19 mice (PS19 vs. PS19-KO). A trend for increased body weight was seen in 11–12-month-old PS19-KO females but not males (Figure 1C). A small but significant increase in tau expression was seen in pre-symptomatic (3 months) PS19-KO mice with a trend in aged (12 months) mice (Figure 1D). In contrast, tau phosphorylation at Ser422 and PHF1 (Ser396/Ser404) epitopes was reduced in aged PS19-KO mice (Figure 1E). This was not attributed to changes in body temperature known to influence tau phosphorylation (63) (Figure 1F). Non-significant trends were noticed in tau aggregation (sarkosyl-insoluble tau) in PS19-KO mice, owing to ~20% of KO mice with more aggregates (Figure 1G and not shown). In addition, no or minimal effects were seen on different markers of brain integrity, including NeuN (neuron), Snap25 (presynaptic), PSD95 (postsynaptic), GFAP (astrocyte), and Iba1 (microglia) (Figure 1H). Taken together, the deletion of the miR-132/212 cluster had no major effects on disease phenotypes tested with divergent effects on tau biology.

We finally investigated a panel of miR-132/212 targets (other than tau) previously associated with tau metabolism or disease, including GSK-3β (26, 61), Mapk3/Erk1 (5, 64), Mapk1/Erk2 (5, 64), p300 (20, 26), Calpain 2 (26), FronA1 (20), and Foxo3a (20, 26). We observed no significant differences caused by miR-132/212 deficiency on endogenous GSK-3β, Mapk1, and Foxo3a in vivo at all ages of study (Figure 2A). On the other hand, and unexpectedly, Mapk3, p300, Calpain2, and Foxo1a levels were reduced in PS19-KO mice, albeit at different ages (Figure 2A).

Of note, we could confirm the regulatory effects of ectopic miR-132 on all genes in cells (Figure 2B). Some cell-type specific effects were noticed, however, including an upregulation of p300 in miR-132-treated HEK293 cells. Representative miRNA qRT-PCR quantification and Western blots of targets are shown in Figure 2C. Inversely, inhibition of endogenous miR-132 in cells had only modest and sporadic effects on a subset of target genes (Figure 2D). Representative results are shown in Figure 2E. Clearly, some discrepancies exist in target gene regulation by miRNAs depending on models and methodological approach. Potential reasons for such paradoxes are discussed below.

Barrier 1: Animal Models

To date, nearly 40 rodent models are available to study different tau species, isoforms and mutations (Alzforum.org) (66). In all cases, the study of human (or humanized) tau is essential to model human pathologies including aggregation and deposition. To our knowledge, only two rodent models contain the complete model-specific variations in gene expression networks. The fact that PS19-KO mice display also lower tau phosphorylation...
and reduced (instead of increased) expression of some miR-132 targets could be accountable to these and other factors as well, including regulatory feedback loops and the absence of the human tau 3′UTR. Fortunately, recent advances in gene editing technologies in vivo (e.g., CRISPR-Cas9) and humanized models (e.g., induced pluripotent stem cells, knock-in mice) can help us to address these issues. The observation that other miRNAs can modulate tau pathology in PS19 mice (40) also opens the door to independent validation studies, that is, taking into consideration the pros and cons of transgenic mice without a human tau 3′UTR.

Barrier 2: Physiological Regulation of tau and Other Targets

Proof-of-principle studies have shown that removing Dicer, the major enzyme responsible for miRNA maturation, induced significant changes in tau metabolism in both neurons (5, 19) and glia (70). However, this approach is largely inadequate to study single miRNAs and targets involved in tau regulation. The function of individual miRNAs is typically (and historically) inferred from overexpression studies in cells or animals, where a single miRNA can regulate tens (up to hundreds) as predicted by bioinformatics tools. However, we know now that most overexpression studies do not reflect physiological context (47, 71–73). Indeed, they can result in the saturation of miRNA maturation products, induce off-target effects, or promote toxicity (74, 75). Lastly, and most importantly, gain-of-function (GOF) tells if a miRNA can exert a specific function, while loss-of-function (LOF) tests whether it is required for that function (72).

Interestingly, recent genetic inactivation studies in C. elegans suggest that some miRNAs function mainly through one or a limited number of master genes (76). Proof-of-principle exists in mice (for miR-155) but not yet in neuronal cells (77, 78). If true, most of the genes (modestly) influenced by miRNAs could be biologically "inactive" (47, 48). The results obtained herein in vivo (Figure 2A), often in theoretical disagreement with
the mode of miRNA function, is somewhat in agreement with this hypothesis, more so given the subtle or negligible effects on tau aggregation and mouse phenotypes in PS19-KO mice. Ideally, the selection of dosage-sensitive genes, combined with prior documented effects on tau in vivo, would be important for functional validation studies.

A variety of technical and other biological factors need also to be considered in the future, including cell-type specificity, spatiotemporal regulation, statistical power, and potential compensation mechanisms from development or aging. Other tau modifications (e.g., acetylation) (79) could also influence its processing, expression, and analysis using more conventional antibodies. Adapted tools and models are now required to fully understand the regulation of tau by individual miRNAs in its physiological milieu, and at the single cell level.

**Barrier 3: Biological State and Context**

There is increasing evidence that cell or biological context also influences miRNA function (80). The probability that miRNAs regulate tau differently according to the pathological state of the brain and peripheral system is therefore quite high. Contributing factors include inflammation, oxidative stress, immune response, and co-pathologies if present. Obviously, such systemic effects are difficult to reproduce in single animal models and even more in cells. And, of course, all of these factors influence miRNA expression to some degree. Interestingly, changes in the immune response and neuroinflammation are known to play a role on tau pathology in PS19 mice (62, 81). While some of these markers seem unaffected in PS19-KO mice (Figure 1H), a detailed analysis remains to be done. The challenge now is to decipher the individual and combined role of above-mentioned factors on miRNA-mediated tau pathology during disease onset.

**FIGURE 2** | Analysis of miR-132 targets in vitro and in vivo. (A) Western blot quantifications of endogenous miR-132 targets (Gsk-3β, Foxo1, Foxo3a, Mapk1/Erk2, Mapk3/Erk1, Calpain2, p300) in PS19 and PS19-KO mice at different ages in the cortex. All significant trends and changes indicate lower expression in KO mice. N = 6–15 per group, mixed sex. Unpaired t-test, where *P < 0.05. (B) Western blot quantification of endogenous miR-132 targets, including tau, in native human SHSY-5Y, human HEK293, and murine Neuro2a cells. Cells were treated with 50 nM miR-132 mimics or scrambled control for 48 h prior to protein extraction. N = 2–4 experiments performed in triplicate. Results are shown as ratios between miR-132 over scrambled mimics (normalized to 1). Unpaired t-test, where *P < 0.05, **P < 0.01, ***P < 0.001. (C) Upper panel: Ectopic miR-132 levels measured by qRT-PCR in each cell line. Relative to scrambled mimic control. Lower panel. Representative western blot analyses. (D) Western blot quantifications of endogenous miR-132 targets. Here, cells were treated with 50 nM miR-132 inhibitors or scrambled control for 48 h. Unpaired t-test, where *P < 0.05, **P < 0.01, ***P < 0.001. (E) Upper panel: Endogenous miR-132 levels measured by qRT-PCR in each cell line following treatment. Relative to scrambled inhibitor control (normalized to 1). Lower panel. Representative western blot analyses. miRNA qRT-PCR were normalized using RNU19 as before (61, 64). Blots were normalized to all proteins using Ponceau or Stain-Free technology. # denotes possible alternate splicing (65) or phosphorylated form of targets. N.A., not available; N.D., not detected; GOF, gain-of-function; LOF, loss-of-function. Error bars represent SEM. In A, the groups of mice were analyzed separately per age. See Supplementary Methods for additional details.
Barrier 4: Cause or Consequence

Understanding why, where, and when miRNAs become misregulated in tauopathies is key to elucidating their function and potential use in diagnostics and therapeutics. Interestingly, changes in miRNA levels occur at all stages of disease in tauopathy mouse models. Examples include miR-142, miR-10, miR-146, miR-155, miR-455, and miR-211 in THY-Tau22 mice (82), miR-142 in Tg4510 mice (83), miR-132, miR-146a, miR-22, and miR-455 in hTau mice (84), and miR-132 in PS19 mice (26). These results suggest that human tau (wildtype or mutant) itself can promote miRNA changes in the mammalian brain. The link with human disease remains, at this stage, uncertain given that most mouse models tested so far (THY-Tau22, Tg4510, PS19) overexpress human mutant tau.

The identification of causal mutations or risk factors within miRNA genes or binding sites provides an alternative strategy to elucidate the cause and consequence relationship between tau and miRNAs in humans. So far, there is little evidence that MAPT 3’UTR polymorphisms are associated with AD risk (85). Nevertheless, a role for 3’UTR polymorphisms in other tauopathies cannot be excluded. Interestingly, a study recently identified a polymorphism within the miR-142 promoter that confers risk for AD (86). Given the complexity of MAPT haplotypes and their importance in disease risk (87), one cannot exclude also a role for miRNA-mediated regulation in this context.

Another strategy to determine causality involves a cure or relief of disease symptoms using miRNA therapeutics. MiRNA mimics can rescue in part disease-related phenotypes in AD and tauopathy mice (48, 61, 69). As inferred above, it will be important to define a therapeutic window for the in vivo use of miRNA oligonucleotides in humans. Note that a miRNA replacement therapy, with the goal of restoring physiological miRNA levels, could provide an attractive alternative to overexpression per se. Taking into consideration all published studies so far, candidate miRNAs for therapeutics include, but are not limited to, miR-132, miR-142, miR-219, miR-455, and miR-146.

CONCLUSION

To date, nearly 30 miRNAs have been implicated in the regulation of tau. The precise role and mode of action of individual miRNAs remains however unsettled. So far, the miR-132/212 cluster stands out for its potential role in regulating tau expression (11, 20, 26, 36, 61), splicing (19), acetylation (26), secretion (26, 88), proteolysis (26, 61), and aggregation (61). This adds to its correlation with disease progression and cognitive impairments in humans and mouse models. However, the choice of living model(s) and hypothesis(es) that need to be addressed are critical. Central elements of tau biology that have not yet been explored is the role of miRNAs in tau function (e.g., microtubule binding, DNA damage, gene expression, cell signaling) and propagation (e.g., spreading and seeding). The importance of miRNAs in familial tauopathies and many other sporadic tauopathies also remain unexplored. Clearly, much more work is needed to fully understand and appreciate the complexity of tau regulation by miRNAs and other non-coding RNAs.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. Requests should be directed to Sebastien.hebert@crchudequebec.ulaval.ca.

ETHICS STATEMENT

The animal study was reviewed and approved by CHU de Québec Research Center Ethics Committee.

AUTHOR CONTRIBUTIONS

EB, JH-R, SR, SP, AL, CG, AT, IS-A, and RK planned and performed the experiments. EP provided valuable material and helped with experimental planning and writing. SH designed, planned and supervised the experiments, and wrote the article. All authors discussed the results and contributed to the final manuscript.

FUNDING

This study was supported by the Canadian Institutes of Health Research (CIHR) and the Fonds de recherche du Québec Santé (FRQS), including a fellowship to JH-R and AT, and the Huntington’s Disease Society of America (HDSA), including a fellowship to SP.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.578720/full#supplementary-material

REFERENCES

1. Sergeant N, Delacourte A, Buee L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta. (2005) 1739:179–97. doi: 10.1016/j.bbadis.2004.06.020
2. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. (2000) 33:95–130. doi: 10.1016/S0165-0173(00)00019-9
3. Buee L, Delacourte A. [Tauopathy and alzheimer disease: a full degenerating process]. Psychol Neuropsychiatr Vieil. (2006) 4:261–73. doi: 10.1684/pnv.2006.0022
4. Follert P, Cremer H, Beclin C. MicroRNAs in brain development and function: a matter of flexibility and stability. Front Mol Neurosci. (2014) 7:5. doi: 10.3389/fnmol.2014.00005
5. Hebert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, Silhavtyrqlu A, et al. Genetic ablation of dicer in adult forebrain neurons results in abnormal
12. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and expression of two tau isoforms. Proc Natl Acad Sci USA. (1988) 85:4051–5. doi: 10.1073/pnas.85.11.4051

13. Aronov S, Marx R, Ginzburg I. Identification of 3’UTR region implicated in tau mRNA stabilization in neuronal cells. J Mol Neurosci. (1999) 12:131-45. doi: 10.1007/BF02736927

14. Aronov S, Aranda G, Behar L, Ginzburg I. Axonal tau mRNA localization coincides with tau protein in living neuronal cells and depends on axonal targeting signal. J Neurosci. (2001) 21:6577-87. doi: 10.1523/JNEUROSCI.21-17-06577.2001

15. Chen JL, Moss WN, Spencer A, Zhang P, Childs-Disney JL, Disney MD. The RNA encoding the microtubule-associated protein tau. Proc Natl Acad Sci USA. (1988) 85:4051-5. doi: 10.1073/pnas.85.11.4051

16. Ye J, Jia R, Xiong H, Ren Q, Zuo W, Lin T, et al. Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT. Cancer Manag Res. (2019) 11:3791-404. doi: 10.2147/CMA.S215427

17. Garcia-Escudero V, Gargiuri M, Martin-Maestro P, Garcia E, Garcia-Escudero R, Avila I. Tau mRNA 3’UTR to CDS ratio is increased in alzheimer disease. Neurosci Lett. (2017) 655:101-8. doi: 10.1016/j.neulet.2017.07.007

18. Hebert SS, Sergeant N, Buee L. MicroRNAs and the regulation of tau metabolism. Int J Alzheimer’s Dis. (2012) 2012:40561. doi: 10.1155/2012/40561

19. Smith PY, Delay C, Girard J, Papon MA, Planel E, Sergeant N, et al. MicroRNA-132 loss is associated with tau exon 10 inclusion and depends on axonal targeting signal. J Neurosci. (2011) 31:14294-306. doi: 10.1523/JNEUROSCI.2924-11.2011

20. Arnes MK, Lannes YA, Alzani J, Cho ME, McCabe JD, Santa-Maria BD, et al. MiR-219 deficiency in alzheimer’s disease contributes to neurodegeneration and memory dysfunction through post-transcriptional regulation of tau kinase network. bioRxiv. (2020) 10.1101/607176

21. Wang X, Tan L, Lu Y, Peng J, Zhu Y, Zhang Y, et al. MiR-132-138 promotes tau phosphorylation by targeting retinoic acid receptor alpha. FEBS Lett. (2015) 589:726-9. doi: 10.1016/j.fle.2015.02.001

22. Banzhaf-Strathmann J, Benito E, May S, Arzberger T, Tahirovic S, Kretzschmar H, et al. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in alzheimer’s disease. EMBO J. (2014) 33:1667-80. doi: 10.15252/embj.201387576

23. Ma X, Liu L, Meng J. MicroRNA-125b promotes neurons cell apoptosis and Tau phosphorylation in alzheimer’s disease. Neurosci Lett. (2017) 661:57-62. doi: 10.1016/j.neulet.2017.09.043

24. Absalon S, Kochanek DM, Raghavan V, Krichevsky AM. MiR-26b, upregulated in alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci. (2013) 33:4465-59. doi: 10.1523/JNEUROSCI.1327-13.2013

25. Hou TY, Zhou Y, Zhu LS, Wang X, Pang P, Wang DQ, et al. Correcting the tau neuropathological progression via the Wnt/β-catenin signaling axis. Sci Rep. (2016) 6:26697. doi: 10.1038/srep26697

26. Hou TY, Zhou Y, Zhu LS, Wang X, Pang P, Wang DQ, et al. Correcting abnormalities in miR-124/PTPN1 signaling rescues tauopathy in alzheimer’s disease. Neurobiol Aging. (2020) 154:441-57. doi: 10.1016/j.neurobiolaging.2019.11.009

27. Wang Y, Veremeyko T, Wong AH, El Fatimy R, Wei Z, Cai W, et al. Down-regulation of miR-132/121 impairs S-nitrosylation balance and induces tau phosphorylation in alzheimer’s disease. Neurobiol Aging. (2017) 51:156-66. doi: 10.1016/j.neurobiolaging.2016.12.015

28. Zhang J, Liu Z, Pei Y, Yang W, Xie C, Long S. MicroRNA-322 cluster promotes tau phosphorylation via targeting brain-derived neurotrophic factor. Biochem Biophys Res Commun. (2018) 493:276-84. doi: 10.1016/j.bbrc.2017.12.127

29. Jiang Y, Xu R, Chen J, Sui Y, Ren L, Li J, et al. MicroRNA-137 inhibits hyperphosphorylation in alzheimer’s disease and targets the CACNA1C gene in transgenic mice and human neuroblastoma SH-SY5Y cells. Med Sci Monit. (2018) 24:5635-44. doi: 10.12659/MSM.908765

Boscher et al. MicroRNAs and Tauopathies

September 2020 | Volume 11 | Article 578720

Frontiers in Neurology | www.frontiersin.org
Boscher et al. MicroRNAs and Tauopathies

44. Zhao ZB, Wu L, Xiong R, Wang LL, Zhang B, Wang C, et al. MicroRNA-922 promotes tau phosphorylation by downregulating ubiquitin carboxy-terminal hydrolase L1 (UCHL1) expression in the pathogenesis of Alzheimer's disease. *Neuroscience*. (2014) 275:232–7. doi: 10.1016/j.neuroscience.2014.06.013

45. Yuan J, Wu Y, Li L, Liu C. MicroRNA-425-5p promotes tau phosphorylation and cell apoptosis in Alzheimer's disease by targeting heat shock protein B2. *J Neural Transm*. (2020) 127:339–46. doi: 10.1007/s00702-019-02134-5

46. Bosson AD, Zamudio JR, Sharp PA. Endogenous miRNA and target concentrations determine susceptibility to potential ceRNA competition. *Mol Cell*. (2014) 56:347–59. doi: 10.1016/j.molcel.2014.09.018

47. Natalia Pinzón BL, Martínez L, Sergeeva A, Presumey J, Apparailly F. The number of biologically relevant microRNA targets has been largely overestimated. *Genome Res*. (2017) 27:11–11. doi: 10.1101/gr.205146.116

48. Pinzón N, Li B, Martínez L, Sergeeva A, Presumey J, Apparailly F, et al. microRNA target prediction programs predict many false positives. *Genome Res*. (2017) 27:234–45. doi: 10.1101/gr.205146.116

49. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfini PP. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? *Cell*. (2011) 146:353–8. doi: 10.1016/j.cell.2011.07.014

50. Denzler R, McGarry SE, Title AC, Agarwal V, Bartel DP, Stoffel M. Impact of MicroRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression. *Mol Cell*. (2016) 64:565–79. doi: 10.1016/j.molcel.2016.09.027

51. Hebert SS, Wang WX, Zhu Q, Nelson PT. A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with Lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. *J Alzheimer's Dis*. (2013) 35:335–48. doi: 10.3233/JAD-122350

52. Babiarz JE, Hsu R, Melton C, Thomas M, Ullian EM, Belloch R. A role for noncanonical microRNAs in the mammalian brain revealed by phenotypic differences in Dgcr8 versus Dicer1 knockouts and small RNA sequencing. *RNA*. (2011) 17:1489–501. doi: 10.1261/rna.244221

53. Hebert SS, Nelson PT. Studying microRNAs in the brain: technical lessons learned from the first ten years. *Exp Neurol*. (2011) 235:397–401. doi: 10.1016/j.expneurol.2011.12.004

54. Pomper N, Liu Y, Hoye ML, Dougherty JD, Miller TM. CNS transcriptome profiling of late-onset Alzheimer's disease provides a database for cell type enriched microRNA profiles: a database for cell type enriched microRNA expression across the mouse central nervous system. *Sci Rep*. (2020) 10:4921. doi: 10.1038/s41598-020-61307-5

55. Wong HK, Veremeoy T, Patel N, Lemere CA, Walsh DM, Esau C, et al. De-repression of FOXO3a death axis by microRNA-132 and –212 causes neuronal apoptosis in Alzheimer's disease. *Hum Mol Genet*. (2013) 22:3077–92. doi: 10.1093/hmg/ddt164

56. Schiller S, Gu W, Hartl D, Gasparoni G, Leidinger P, Keller C, et al. The miRNAome of Alzheimer's disease: consistent downregulation of the miR-132/212 cluster. *Neurobiol Aging*. (2017) 50:167.e1–e10. doi: 10.1016/j.neurobiolaging.2016.09.019

57. Annese A, Manzari C, Lionetti C, Picardi E, Horner DS, Chiara M, et al. Microglial microRNAs mediate sex-specific responses to tau pathology. *Nat Neurosci*. (2020) 23:167–71. doi: 10.1038/s41593-019-0560-7

58. Sin JH, Yun H, Chen P, Yang C, Zhou X, Kang SG, et al. Differential sensitivity of target genes to translational repression by miR-17–92. *PLoS Genet*. (2013) 9:e1006623. doi: 10.1371/journal.pgen.1006623

59. Vidgal JA, Ventura A. The biological functions of miRNAs: lessons from in vivo studies. *Trends Cell Biol*. (2015) 25:137–47. doi: 10.1016/j.tcb.2014.11.004

60. Jin J, Kim SN, Liu X, Zhang H, Zhang C, Seo JS, et al. miR-17–92 cluster regulates adult hippocampal neurogenesis, anxiety, and depression. *Cell Rep*. (2016) 16:1653–63. doi: 10.1016/j.celrep.2016.06.101

61. Jin HY, Gonzalez-Martín A, Miletic AV, Lai M, Knight S, Sabourin-Ghomi M, et al. Transfection of microRNA mimics should be used with caution. *Front Genet*. (2015) 6:340. doi: 10.3389/fgene.2015.00340

62. Merhautova J, Demlova R, Slaby O. MicroRNA-based therapy in animal models of selected gastrointestinal cancers. *Front Pharmacol*. (2016) 7:329. doi: 10.3389/fphar.2016.00329

63. Park CY, Choi YS, Manusmit M. Analysis of microRNA knockouts in mice. *Mol Ther Nucleic Acids*. (2020) 20:613093. doi: 10.1038/s41397-020-01611-z

64. Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbins DP, et al. MicroRNA-155 suppresses activation-induced cytokine deaminase-mediated Myc-Igh translocation. *Immunity*. (2008) 28:630–8. doi: 10.1016/j.immuni.2008.04.002

65. Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, et al. MicroRNA-155 is a negative regulator of activation-induced cytokine deaminase. *Immunity*. (2008) 28:621–9. doi: 10.1016/j.immuni.2008.03.015

66. Gorsky MK, Burnouf S, Sofola-Adesakin O, Dols J, Augustin H, Weigelt C, et al. Analysis of microRNA-146a agomir rescued the pathological process and cognitive impairment in an AD mouse model. *Mol Ther Nucleic Acids*. (2019) 18:681–95. doi: 10.1038/s41397-019.1002.002

67. Kordama L, Guzman E, Etchegary IL, Ly Y, Sayed FA, Zhou L, et al. Microglial microRNA-155 mediates sex-specific responses to tau pathology. *Nat Neurosci*. (2020) 23:167–71. doi: 10.1038/s41593-019-0560-7

68. Jin HY, Oda H, Chen P, Yang C, Zhou X, Kang SG, et al. Differential sensitivity of target genes to translational repression by miR-17–92. *PLoS Genet*. (2013) 9:e1006623. doi: 10.1371/journal.pgen.1006623

69. Park CY, Choi YS, Manusmit M. Analysis of microRNA knockouts in mice. *Mol Ther Nucleic Acids*. (2020) 20:613093. doi: 10.1038/s41397-020-01611-z
82. Sierksma A, Lu A, Salta E, Vanden Eynden E, Callaerts-Vegh Z, D’Hooge R, et al. Deregulation of neuronal miRNAs induced by amyloid-beta or TAU pathology. *Mol Neurodegener.* (2018) 13:54. doi: 10.1186/s13024-018-0285-1

83. Sharma S, Khadimallah I, Corya AW, Ali YO, Rao X, Liu Y, et al. Presymptomatic change in microRNAs modulates Tau pathology. *Sci Rep.* (2018) 8:9251. doi: 10.1038/s41598-018-27527-6

84. Lauretti E, Dincer O, Pratico D. Regional and temporal miRNAs expression profile in a transgenic mouse model of tauopathy: implication for its pathogenesis. *Mol Psychiatry.* (2020) doi: 10.1038/s41380-020-0655-2

85. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet.* (2019) 51:414–30. doi: 10.1038/s41588-019-0358-2

86. Ghanbari M, Munshi ST, Ma B, Lendemeijer B, Bansal S, Adams HH, et al. A functional variant in the miR-142 promoter modulating its expression and conferring risk of alzheimer disease. *Hum Mutat.* (2019) 40:2131–45. doi: 10.1002/humu.23872

87. Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, et al. The MAPT H1 haplotype is associated with tangle-predominant dementia. *Acta Neuropathol.* (2012) 124:693–704. doi: 10.1007/s00401-012-1017-1

88. Cha DJ, Mengel D, Mustapic M, Liu W, Selkoe DJ, Kapogiannis D, et al. miR-212 and miR-132 are downregulated in neurally derived plasma exosomes of alzheimer’s patients. *Front Neurosci.* (2019) 13:1208. doi: 10.3389/fnins.2019.01208

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Boscher, Hernandez-Rapp, Pétry, Keraudren, Rainone, Loiselle, Goupil, Turgeon, St-Amour, Planel and Hébert. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*